Found 45 hits of Enzyme Inhibition Constant Data Target/Host
(Institution) | Ligand | Target/Host
Links | Ligand
Links | Trg + Lig
Links | Ki
nM | ΔG°
kJ/mole | IC50
nM | Kd
nM | EC50/IC50
nM | koff
s-1 | kon
M-1s-1 | pH | Temp
°C |
|---|
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314095
(CHEMBL1090633)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(N)=N)NCCNC(=O)CCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](Cc3ccccc3)C(=O)NCC(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CSSC2(C)C)C(N)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C148H205N39O34S4/c1-81(2)59-109-137(214)170-97(61-89-43-47-93(190)48-44-89)121(200)143(220)186-57-29-41-107(186)135(212)176-105(125(149)202)77-222-224-147(7,8)123(141(218)178-119(83(5)188)139(216)161-71-113(194)168-103(67-91-69-155-79-165-91)131(208)172-99(63-85-31-19-15-20-32-85)127(204)163-73-115(196)182(11)75-117(198)184(109)13)180-133(210)101(65-87-35-23-17-24-36-87)174-129(206)95(39-27-53-159-145(151)152)157-55-56-158-111(192)51-52-112(193)167-96(40-28-54-160-146(153)154)130(207)175-102(66-88-37-25-18-26-38-88)134(211)181-124-142(219)179-120(84(6)189)140(217)162-72-114(195)169-104(68-92-70-156-80-166-92)132(209)173-100(64-86-33-21-16-22-34-86)128(205)164-74-116(197)183(12)76-118(199)185(14)110(60-82(3)4)138(215)171-98(62-90-45-49-94(191)50-46-90)122(201)144(221)187-58-30-42-108(187)136(213)177-106(126(150)203)78-223-225-148(124,9)10/h15-26,31-38,43-50,69-70,79-84,95-110,119-120,123-124,157,188-191H,27-30,39-42,51-68,71-78H2,1-14H3,(H2,149,202)(H2,150,203)(H,155,165)(H,156,166)(H,158,192)(H,161,216)(H,162,217)(H,163,204)(H,164,205)(H,167,193)(H,168,194)(H,169,195)(H,170,214)(H,171,215)(H,172,208)(H,173,209)(H,174,206)(H,175,207)(H,176,212)(H,177,213)(H,178,218)(H,179,219)(H,180,210)(H,181,211)(H4,151,152,159)(H4,153,154,160)/t83-,84-,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,119+,120+,123-,124-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet 
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 1.60 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314094
(CHEMBL1090632)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CCNC(=O)CCNC(=O)CCNC(=O)CN(C)CCNC(=O)CCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](Cc3ccccc3)C(=O)NCC(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CSSC2(C)C)C(N)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C160H225N43O38S4/c1-89(2)66-117-149(234)185-105(68-97-44-48-101(206)49-45-97)133(220)155(240)202-63-30-42-115(202)147(232)191-113(137(161)222)85-242-244-159(7,8)135(153(238)193-131(91(5)204)151(236)175-78-124(213)183-111(74-99-76-167-87-179-99)143(228)187-107(70-93-32-20-16-21-33-93)139(224)177-80-127(216)198(12)83-129(218)200(117)14)195-145(230)109(72-95-36-24-18-25-37-95)189-141(226)103(40-28-57-173-157(163)164)181-122(211)53-52-119(208)172-62-65-197(11)82-126(215)171-60-55-121(210)169-59-54-120(209)170-61-56-123(212)182-104(41-29-58-174-158(165)166)142(227)190-110(73-96-38-26-19-27-39-96)146(231)196-136-154(239)194-132(92(6)205)152(237)176-79-125(214)184-112(75-100-77-168-88-180-100)144(229)188-108(71-94-34-22-17-23-35-94)140(225)178-81-128(217)199(13)84-130(219)201(15)118(67-90(3)4)150(235)186-106(69-98-46-50-102(207)51-47-98)134(221)156(241)203-64-31-43-116(203)148(233)192-114(138(162)223)86-243-245-160(136,9)10/h16-27,32-39,44-51,76-77,87-92,103-118,131-132,135-136,204-207H,28-31,40-43,52-75,78-86H2,1-15H3,(H2,161,222)(H2,162,223)(H,167,179)(H,168,180)(H,169,210)(H,170,209)(H,171,215)(H,172,208)(H,175,236)(H,176,237)(H,177,224)(H,178,225)(H,181,211)(H,182,212)(H,183,213)(H,184,214)(H,185,234)(H,186,235)(H,187,228)(H,188,229)(H,189,226)(H,190,227)(H,191,232)(H,192,233)(H,193,238)(H,194,239)(H,195,230)(H,196,231)(H4,163,164,173)(H4,165,166,174)/t91-,92-,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,131+,132+,135-,136-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 2.40 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314105
(CHEMBL1090970 | N1,N4-bis((S)-1-((S)-1-((3R,8R,11S...)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](Cc3ccccc3)C(=O)NCC(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CSSC2(C)C)C(N)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C146H200N38O34S4/c1-79(2)57-107-135(211)167-95(59-87-43-47-91(187)48-44-87)119(197)141(217)183-55-29-41-105(183)133(209)173-103(123(147)199)75-219-221-145(7,8)121(139(215)175-117(81(5)185)137(213)157-69-111(191)165-101(65-89-67-153-77-161-89)129(205)169-97(61-83-31-19-15-20-32-83)125(201)159-71-113(193)179(11)73-115(195)181(107)13)177-131(207)99(63-85-35-23-17-24-36-85)171-127(203)93(39-27-53-155-143(149)150)163-109(189)51-52-110(190)164-94(40-28-54-156-144(151)152)128(204)172-100(64-86-37-25-18-26-38-86)132(208)178-122-140(216)176-118(82(6)186)138(214)158-70-112(192)166-102(66-90-68-154-78-162-90)130(206)170-98(62-84-33-21-16-22-34-84)126(202)160-72-114(194)180(12)74-116(196)182(14)108(58-80(3)4)136(212)168-96(60-88-45-49-92(188)50-46-88)120(198)142(218)184-56-30-42-106(184)134(210)174-104(124(148)200)76-220-222-146(122,9)10/h15-26,31-38,43-50,67-68,77-82,93-108,117-118,121-122,185-188H,27-30,39-42,51-66,69-76H2,1-14H3,(H2,147,199)(H2,148,200)(H,153,161)(H,154,162)(H,157,213)(H,158,214)(H,159,201)(H,160,202)(H,163,189)(H,164,190)(H,165,191)(H,166,192)(H,167,211)(H,168,212)(H,169,205)(H,170,206)(H,171,203)(H,172,204)(H,173,209)(H,174,210)(H,175,215)(H,176,216)(H,177,207)(H,178,208)(H4,149,150,155)(H4,151,152,156)/t81-,82-,93+,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,117+,118+,121-,122-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 2.40 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314093
(CHEMBL1090631)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CCC(=O)NCCN(C)CC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](Cc3ccccc3)C(=O)NCC(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CSSC2(C)C)C(N)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C151H210N40O35S4/c1-83(2)60-111-140(219)173-99(62-91-44-48-95(194)49-45-91)124(205)146(225)190-57-30-42-109(190)138(217)179-107(128(152)207)79-227-229-150(7,8)126(144(223)181-122(85(5)192)142(221)163-72-115(198)171-105(68-93-70-158-81-167-93)134(213)175-101(64-87-32-20-16-21-33-87)130(209)165-74-118(201)186(12)77-120(203)188(111)14)183-136(215)103(66-89-36-24-18-25-37-89)177-132(211)97(40-28-54-161-148(154)155)169-114(197)53-52-113(196)160-56-59-185(11)76-117(200)170-98(41-29-55-162-149(156)157)133(212)178-104(67-90-38-26-19-27-39-90)137(216)184-127-145(224)182-123(86(6)193)143(222)164-73-116(199)172-106(69-94-71-159-82-168-94)135(214)176-102(65-88-34-22-17-23-35-88)131(210)166-75-119(202)187(13)78-121(204)189(15)112(61-84(3)4)141(220)174-100(63-92-46-50-96(195)51-47-92)125(206)147(226)191-58-31-43-110(191)139(218)180-108(129(153)208)80-228-230-151(127,9)10/h16-27,32-39,44-51,70-71,81-86,97-112,122-123,126-127,192-195H,28-31,40-43,52-69,72-80H2,1-15H3,(H2,152,207)(H2,153,208)(H,158,167)(H,159,168)(H,160,196)(H,163,221)(H,164,222)(H,165,209)(H,166,210)(H,169,197)(H,170,200)(H,171,198)(H,172,199)(H,173,219)(H,174,220)(H,175,213)(H,176,214)(H,177,211)(H,178,212)(H,179,217)(H,180,218)(H,181,223)(H,182,224)(H,183,215)(H,184,216)(H4,154,155,161)(H4,156,157,162)/t85-,86-,97+,98+,99?,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,122+,123+,126-,127-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 2.60 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314090
(CHEMBL1090278 | N-[(1S)-1-{[(1S)-1-{[(5S,8S,15S,18...)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN2CCC[C@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CCC(=O)NCCN(C)CC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H]3C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc4cnc[nH]4)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@H]4CCCN(CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](Cc5ccc(O)cc5)C(=O)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CSSC3(C)C)C(N)=O)C4=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]3CCCN3C(=O)C(=O)[C@H](Cc3ccc(O)cc3)NC1=O)C(N)=O)[C@@H](C)O)C2=O |r| Show InChI InChI=1S/C155H214N40O35S4/c1-85(2)64-115-142(221)177-103(66-93-46-50-97(198)51-47-93)126(207)150(229)194-61-30-44-113(194)140(219)183-111(130(156)209)81-231-233-154(7,8)128(146(225)185-124(87(5)196)144(223)167-76-119(202)173-109(72-95-74-162-83-169-95)136(215)181-105(68-89-32-18-14-19-33-89)134(213)175-101-42-28-59-192(148(101)227)79-122(205)190(115)12)187-138(217)107(70-91-36-22-16-23-37-91)179-132(211)99(40-26-56-165-152(158)159)171-118(201)55-54-117(200)164-58-63-189(11)78-121(204)172-100(41-27-57-166-153(160)161)133(212)180-108(71-92-38-24-17-25-39-92)139(218)188-129-147(226)186-125(88(6)197)145(224)168-77-120(203)174-110(73-96-75-163-84-170-96)137(216)182-106(69-90-34-20-15-21-35-90)135(214)176-102-43-29-60-193(149(102)228)80-123(206)191(13)116(65-86(3)4)143(222)178-104(67-94-48-52-98(199)53-49-94)127(208)151(230)195-62-31-45-114(195)141(220)184-112(131(157)210)82-232-234-155(129,9)10/h14-25,32-39,46-53,74-75,83-88,99-116,124-125,128-129,196-199H,26-31,40-45,54-73,76-82H2,1-13H3,(H2,156,209)(H2,157,210)(H,162,169)(H,163,170)(H,164,200)(H,167,223)(H,168,224)(H,171,201)(H,172,204)(H,173,202)(H,174,203)(H,175,213)(H,176,214)(H,177,221)(H,178,222)(H,179,211)(H,180,212)(H,181,215)(H,182,216)(H,183,219)(H,184,220)(H,185,225)(H,186,226)(H,187,217)(H,188,218)(H4,158,159,165)(H4,160,161,166)/t87-,88-,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,124+,125+,128-,129-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 3.90 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314102
(CHEMBL1090640)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CN(C)CCNC(=O)CNC(=O)[C@@H]2CSSC(C)(C)[C@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](Cc3ccccc3)C(=O)NCC(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)C(=O)N3CCC[C@H]3C(=O)N2)C(C)(C)SSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C149H208N40O34S4/c1-82(2)58-110-138(216)171-98(60-90-44-48-94(192)49-45-90)122(202)144(222)188-55-30-42-108(188)136(214)177-106(126(151)204)78-224-226-148(7,8)124(142(220)179-120(84(5)190)140(218)162-71-113(195)169-104(66-92-68-156-80-166-92)132(210)174-100(62-86-32-20-16-21-33-86)128(206)164-73-116(198)184(12)76-118(200)186(110)14)182-135(213)103(65-89-38-26-19-27-39-89)176-131(209)97(41-29-53-160-147(154)155)168-115(197)75-183(11)57-54-158-112(194)70-161-130(208)107-79-225-227-149(9,10)125(181-134(212)102(64-88-36-24-18-25-37-88)173-127(205)96(150)40-28-52-159-146(152)153)143(221)180-121(85(6)191)141(219)163-72-114(196)170-105(67-93-69-157-81-167-93)133(211)175-101(63-87-34-22-17-23-35-87)129(207)165-74-117(199)185(13)77-119(201)187(15)111(59-83(3)4)139(217)172-99(61-91-46-50-95(193)51-47-91)123(203)145(223)189-56-31-43-109(189)137(215)178-107/h16-27,32-39,44-51,68-69,80-85,96-111,120-121,124-125,190-193H,28-31,40-43,52-67,70-79,150H2,1-15H3,(H2,151,204)(H,156,166)(H,157,167)(H,158,194)(H,161,208)(H,162,218)(H,163,219)(H,164,206)(H,165,207)(H,168,197)(H,169,195)(H,170,196)(H,171,216)(H,172,217)(H,173,205)(H,174,210)(H,175,211)(H,176,209)(H,177,214)(H,178,215)(H,179,220)(H,180,221)(H,181,212)(H,182,213)(H4,152,153,159)(H4,154,155,160)/t84-,85-,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,120+,121+,124-,125-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 3.90 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314103
((R,S,S,3R,3'R,8R,8'R,11S,11'S,17S,17'S,20S,20'S,29...)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](N)CCCNC(N)=N)C(C)(C)SSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)NCC(=O)NCCNCCNC(=O)CNC(=O)[C@@H]1CSSC(C)(C)[C@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](Cc2ccccc2)C(=O)NCC(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)C(=O)N2CCC[C@H]2C(=O)N1)[C@@H](C)O |r| Show InChI InChI=1S/C150H211N41O34S4/c1-83(2)59-111-139(218)174-99(61-91-43-47-95(194)48-44-91)123(204)145(224)190-57-29-41-109(190)137(216)180-107(79-226-228-149(7,8)125(184-135(214)103(65-89-35-23-17-24-36-89)176-127(206)97(151)39-27-51-162-147(153)154)143(222)182-121(85(5)192)141(220)166-73-115(198)172-105(67-93-69-158-81-170-93)133(212)178-101(63-87-31-19-15-20-32-87)129(208)168-75-117(200)186(11)77-119(202)188(111)13)131(210)164-71-113(196)160-55-53-157-54-56-161-114(197)72-165-132(211)108-80-227-229-150(9,10)126(185-136(215)104(66-90-37-25-18-26-38-90)177-128(207)98(152)40-28-52-163-148(155)156)144(223)183-122(86(6)193)142(221)167-74-116(199)173-106(68-94-70-159-82-171-94)134(213)179-102(64-88-33-21-16-22-34-88)130(209)169-76-118(201)187(12)78-120(203)189(14)112(60-84(3)4)140(219)175-100(62-92-45-49-96(195)50-46-92)124(205)146(225)191-58-30-42-110(191)138(217)181-108/h15-26,31-38,43-50,69-70,81-86,97-112,121-122,125-126,157,192-195H,27-30,39-42,51-68,71-80,151-152H2,1-14H3,(H,158,170)(H,159,171)(H,160,196)(H,161,197)(H,164,210)(H,165,211)(H,166,220)(H,167,221)(H,168,208)(H,169,209)(H,172,198)(H,173,199)(H,174,218)(H,175,219)(H,176,206)(H,177,207)(H,178,212)(H,179,213)(H,180,216)(H,181,217)(H,182,222)(H,183,223)(H,184,214)(H,185,215)(H4,153,154,162)(H4,155,156,163)/t85-,86-,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,121+,122+,125-,126-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 4.20 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314100
((S)-N1,N4-bis((S)-1-((S)-1-((3R,8R,11S,17S,20S,29S...)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)C[C@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](Cc3ccccc3)C(=O)NCC(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CSSC2(C)C)C(N)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C147H202N38O34S4/c1-79(2)56-108-136(212)168-96(59-88-44-48-92(188)49-45-88)119(197)142(218)184-54-30-42-106(184)134(210)174-104(123(148)199)75-220-222-146(8,9)121(140(216)176-117(82(6)186)138(214)158-69-111(191)165-102(65-90-67-154-77-162-90)130(206)170-98(61-84-32-20-16-21-33-84)126(202)160-71-113(193)180(12)73-115(195)182(108)14)178-132(208)100(63-86-36-24-18-25-37-86)172-128(204)94(40-28-52-156-144(150)151)164-110(190)58-81(5)125(201)167-95(41-29-53-157-145(152)153)129(205)173-101(64-87-38-26-19-27-39-87)133(209)179-122-141(217)177-118(83(7)187)139(215)159-70-112(192)166-103(66-91-68-155-78-163-91)131(207)171-99(62-85-34-22-17-23-35-85)127(203)161-72-114(194)181(13)74-116(196)183(15)109(57-80(3)4)137(213)169-97(60-89-46-50-93(189)51-47-89)120(198)143(219)185-55-31-43-107(185)135(211)175-105(124(149)200)76-221-223-147(122,10)11/h16-27,32-39,44-51,67-68,77-83,94-109,117-118,121-122,186-189H,28-31,40-43,52-66,69-76H2,1-15H3,(H2,148,199)(H2,149,200)(H,154,162)(H,155,163)(H,158,214)(H,159,215)(H,160,202)(H,161,203)(H,164,190)(H,165,191)(H,166,192)(H,167,201)(H,168,212)(H,169,213)(H,170,206)(H,171,207)(H,172,204)(H,173,205)(H,174,210)(H,175,211)(H,176,216)(H,177,217)(H,178,208)(H,179,209)(H4,150,151,156)(H4,152,153,157)/t81-,82+,83+,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,117-,118-,121+,122+/m0/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 4.60 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314098
(CHEMBL1090636)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CN(C)CC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](Cc3ccccc3)C(=O)NCC(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CSSC2(C)C)C(N)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C147H203N39O34S4/c1-80(2)56-108-136(213)168-96(58-88-44-48-92(189)49-45-88)120(199)142(219)185-54-30-42-106(185)134(211)174-104(124(148)201)76-221-223-146(7,8)122(140(217)176-118(82(5)187)138(215)158-68-110(191)166-102(64-90-66-154-78-162-90)130(207)170-98(60-84-32-20-16-21-33-84)126(203)160-70-114(195)181(12)74-116(197)183(108)14)178-132(209)100(62-86-36-24-18-25-37-86)172-128(205)94(40-28-52-156-144(150)151)164-112(193)72-180(11)73-113(194)165-95(41-29-53-157-145(152)153)129(206)173-101(63-87-38-26-19-27-39-87)133(210)179-123-141(218)177-119(83(6)188)139(216)159-69-111(192)167-103(65-91-67-155-79-163-91)131(208)171-99(61-85-34-22-17-23-35-85)127(204)161-71-115(196)182(13)75-117(198)184(15)109(57-81(3)4)137(214)169-97(59-89-46-50-93(190)51-47-89)121(200)143(220)186-55-31-43-107(186)135(212)175-105(125(149)202)77-222-224-147(123,9)10/h16-27,32-39,44-51,66-67,78-83,94-109,118-119,122-123,187-190H,28-31,40-43,52-65,68-77H2,1-15H3,(H2,148,201)(H2,149,202)(H,154,162)(H,155,163)(H,158,215)(H,159,216)(H,160,203)(H,161,204)(H,164,193)(H,165,194)(H,166,191)(H,167,192)(H,168,213)(H,169,214)(H,170,207)(H,171,208)(H,172,205)(H,173,206)(H,174,211)(H,175,212)(H,176,217)(H,177,218)(H,178,209)(H,179,210)(H4,150,151,156)(H4,152,153,157)/t82-,83-,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,118+,119+,122-,123-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 4.70 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314096
(CHEMBL1090634)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CCOCCOCCOCCOCCOCCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](Cc3ccccc3)C(=O)NCC(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CSSC2(C)C)C(N)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C156H220N38O39S4/c1-89(2)67-117-145(221)177-105(69-97-43-47-101(197)48-44-97)129(207)151(227)193-55-29-41-115(193)143(219)183-113(133(157)209)85-234-236-155(7,8)131(149(225)185-127(91(5)195)147(223)167-79-121(201)175-111(75-99-77-163-87-171-99)139(215)179-107(71-93-31-19-15-20-32-93)135(211)169-81-123(203)189(11)83-125(205)191(117)13)187-141(217)109(73-95-35-23-17-24-36-95)181-137(213)103(39-27-53-165-153(159)160)173-119(199)51-57-229-59-61-231-63-65-233-66-64-232-62-60-230-58-52-120(200)174-104(40-28-54-166-154(161)162)138(214)182-110(74-96-37-25-18-26-38-96)142(218)188-132-150(226)186-128(92(6)196)148(224)168-80-122(202)176-112(76-100-78-164-88-172-100)140(216)180-108(72-94-33-21-16-22-34-94)136(212)170-82-124(204)190(12)84-126(206)192(14)118(68-90(3)4)146(222)178-106(70-98-45-49-102(198)50-46-98)130(208)152(228)194-56-30-42-116(194)144(220)184-114(134(158)210)86-235-237-156(132,9)10/h15-26,31-38,43-50,77-78,87-92,103-118,127-128,131-132,195-198H,27-30,39-42,51-76,79-86H2,1-14H3,(H2,157,209)(H2,158,210)(H,163,171)(H,164,172)(H,167,223)(H,168,224)(H,169,211)(H,170,212)(H,173,199)(H,174,200)(H,175,201)(H,176,202)(H,177,221)(H,178,222)(H,179,215)(H,180,216)(H,181,213)(H,182,214)(H,183,219)(H,184,220)(H,185,225)(H,186,226)(H,187,217)(H,188,218)(H4,159,160,165)(H4,161,162,166)/t91-,92-,103+,104+,105+,106+,107+,108?,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,127+,128+,131-,132-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 4.80 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314099
(CHEMBL1090637 | N1,N5-bis((S)-1-((S)-1-((3R,8R,11S...)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CC(C)(C)CC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](Cc3ccccc3)C(=O)NCC(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CSSC2(C)C)C(N)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C149H206N38O34S4/c1-81(2)57-109-137(214)170-97(59-89-45-49-93(190)50-46-89)121(200)143(220)186-55-31-43-107(186)135(212)176-105(125(150)202)77-222-224-148(9,10)123(141(218)178-119(83(5)188)139(216)160-71-113(194)168-103(65-91-69-156-79-164-91)131(208)172-99(61-85-33-21-17-22-34-85)127(204)162-73-115(196)182(13)75-117(198)184(109)15)180-133(210)101(63-87-37-25-19-26-38-87)174-129(206)95(41-29-53-158-145(152)153)166-111(192)67-147(7,8)68-112(193)167-96(42-30-54-159-146(154)155)130(207)175-102(64-88-39-27-20-28-40-88)134(211)181-124-142(219)179-120(84(6)189)140(217)161-72-114(195)169-104(66-92-70-157-80-165-92)132(209)173-100(62-86-35-23-18-24-36-86)128(205)163-74-116(197)183(14)76-118(199)185(16)110(58-82(3)4)138(215)171-98(60-90-47-51-94(191)52-48-90)122(201)144(221)187-56-32-44-108(187)136(213)177-106(126(151)203)78-223-225-149(124,11)12/h17-28,33-40,45-52,69-70,79-84,95-110,119-120,123-124,188-191H,29-32,41-44,53-68,71-78H2,1-16H3,(H2,150,202)(H2,151,203)(H,156,164)(H,157,165)(H,160,216)(H,161,217)(H,162,204)(H,163,205)(H,166,192)(H,167,193)(H,168,194)(H,169,195)(H,170,214)(H,171,215)(H,172,208)(H,173,209)(H,174,206)(H,175,207)(H,176,212)(H,177,213)(H,178,218)(H,179,219)(H,180,210)(H,181,211)(H4,152,153,158)(H4,154,155,159)/t83-,84-,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,119+,120+,123-,124-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 5 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314097
(CHEMBL1090635 | N1,N1'-(ethane-1,2-diyl)bis(N4-((S...)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CCC(=O)N(C)CCN(C)C(=O)CCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](Cc3ccccc3)C(=O)NCC(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CSSC2(C)C)C(N)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C154H214N40O36S4/c1-85(2)63-113-143(223)175-101(65-93-45-49-97(197)50-46-93)127(209)149(229)193-59-31-43-111(193)141(221)181-109(131(155)211)81-231-233-153(7,8)129(147(227)183-125(87(5)195)145(225)165-75-117(201)173-107(71-95-73-161-83-169-95)137(217)177-103(67-89-33-21-17-22-34-89)133(213)167-77-121(205)189(13)79-123(207)191(113)15)185-139(219)105(69-91-37-25-19-26-38-91)179-135(215)99(41-29-57-163-151(157)158)171-115(199)53-55-119(203)187(11)61-62-188(12)120(204)56-54-116(200)172-100(42-30-58-164-152(159)160)136(216)180-106(70-92-39-27-20-28-40-92)140(220)186-130-148(228)184-126(88(6)196)146(226)166-76-118(202)174-108(72-96-74-162-84-170-96)138(218)178-104(68-90-35-23-18-24-36-90)134(214)168-78-122(206)190(14)80-124(208)192(16)114(64-86(3)4)144(224)176-102(66-94-47-51-98(198)52-48-94)128(210)150(230)194-60-32-44-112(194)142(222)182-110(132(156)212)82-232-234-154(130,9)10/h17-28,33-40,45-52,73-74,83-88,99-114,125-126,129-130,195-198H,29-32,41-44,53-72,75-82H2,1-16H3,(H2,155,211)(H2,156,212)(H,161,169)(H,162,170)(H,165,225)(H,166,226)(H,167,213)(H,168,214)(H,171,199)(H,172,200)(H,173,201)(H,174,202)(H,175,223)(H,176,224)(H,177,217)(H,178,218)(H,179,215)(H,180,216)(H,181,221)(H,182,222)(H,183,227)(H,184,228)(H,185,219)(H,186,220)(H4,157,158,163)(H4,159,160,164)/t87-,88-,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,125+,126+,129-,130-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 5.20 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314101
((S)-N1,N5-bis((S)-1-((S)-1-((3R,8R,11S,17S,20S,29S...)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CC[C@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](Cc3ccccc3)C(=O)NCC(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CSSC2(C)C)C(N)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C148H204N38O34S4/c1-80(2)58-109-137(213)169-97(60-89-45-49-93(189)50-46-89)120(198)143(219)185-56-30-42-107(185)135(211)175-105(124(149)200)76-221-223-147(8,9)122(141(217)177-118(83(6)187)139(215)159-70-112(192)166-103(66-91-68-155-78-163-91)131(207)171-99(62-85-32-20-16-21-33-85)127(203)161-72-114(194)181(12)74-116(196)183(109)14)179-133(209)101(64-87-36-24-18-25-37-87)173-129(205)95(40-28-54-157-145(151)152)165-111(191)53-44-82(5)126(202)168-96(41-29-55-158-146(153)154)130(206)174-102(65-88-38-26-19-27-39-88)134(210)180-123-142(218)178-119(84(7)188)140(216)160-71-113(193)167-104(67-92-69-156-79-164-92)132(208)172-100(63-86-34-22-17-23-35-86)128(204)162-73-115(195)182(13)75-117(197)184(15)110(59-81(3)4)138(214)170-98(61-90-47-51-94(190)52-48-90)121(199)144(220)186-57-31-43-108(186)136(212)176-106(125(150)201)77-222-224-148(123,10)11/h16-27,32-39,45-52,68-69,78-84,95-110,118-119,122-123,187-190H,28-31,40-44,53-67,70-77H2,1-15H3,(H2,149,200)(H2,150,201)(H,155,163)(H,156,164)(H,159,215)(H,160,216)(H,161,203)(H,162,204)(H,165,191)(H,166,192)(H,167,193)(H,168,202)(H,169,213)(H,170,214)(H,171,207)(H,172,208)(H,173,205)(H,174,206)(H,175,211)(H,176,212)(H,177,217)(H,178,218)(H,179,209)(H,180,210)(H4,151,152,157)(H4,153,154,158)/t82-,83+,84+,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,118-,119-,122+,123+/m0/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 5.60 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314091
(CHEMBL1090279 | N-[(1S)-1-{[(1S)-1-{[(5S,8S,15S,18...)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN2CCC[C@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)CNC(=O)[C@H](C)N(C)C(=O)[C@@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CCC(=O)NCCN(C)CC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H]3C(=O)N(C)[C@@H](C)C(=O)NCC(=O)N[C@@H](Cc4cnc[nH]4)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@H]4CCCN(CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](Cc5ccc(O)cc5)C(=O)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CSSC3(C)C)C(N)=O)C4=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]3CCCN3C(=O)C(=O)[C@H](Cc3ccc(O)cc3)NC1=O)C(N)=O)C2=O |r| Show InChI InChI=1S/C155H214N40O33S4/c1-87(2)66-117-144(221)177-105(68-95-48-52-99(196)53-49-95)126(205)148(225)194-63-32-46-115(194)142(219)183-113(130(156)207)83-229-231-154(7,8)128(150(227)188(12)89(5)132(209)167-78-121(200)173-111(74-97-76-162-85-169-97)138(215)181-107(70-91-34-20-16-21-35-91)136(213)175-103-44-30-61-192(146(103)223)81-124(203)190(117)14)185-140(217)109(72-93-38-24-18-25-39-93)179-134(211)101(42-28-58-165-152(158)159)171-120(199)57-56-119(198)164-60-65-187(11)80-123(202)172-102(43-29-59-166-153(160)161)135(212)180-110(73-94-40-26-19-27-41-94)141(218)186-129-151(228)189(13)90(6)133(210)168-79-122(201)174-112(75-98-77-163-86-170-98)139(216)182-108(71-92-36-22-17-23-37-92)137(214)176-104-45-31-62-193(147(104)224)82-125(204)191(15)118(67-88(3)4)145(222)178-106(69-96-50-54-100(197)55-51-96)127(206)149(226)195-64-33-47-116(195)143(220)184-114(131(157)208)84-230-232-155(129,9)10/h16-27,34-41,48-55,76-77,85-90,101-118,128-129,196-197H,28-33,42-47,56-75,78-84H2,1-15H3,(H2,156,207)(H2,157,208)(H,162,169)(H,163,170)(H,164,198)(H,167,209)(H,168,210)(H,171,199)(H,172,202)(H,173,200)(H,174,201)(H,175,213)(H,176,214)(H,177,221)(H,178,222)(H,179,211)(H,180,212)(H,181,215)(H,182,216)(H,183,219)(H,184,220)(H,185,217)(H,186,218)(H4,158,159,165)(H4,160,161,166)/t89-,90-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,128+,129+/m0/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 18 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314104
(CHEMBL1090969 | N1,N4-bis((S)-1-((S)-1-((3R,8R,11S...)Show SMILES [#6]-[#6](-[#6])-[#6]-[#6@@H]-1-[#7](-[#6])-[#6](=O)-[#6]-[#7](-[#6])-[#6](=O)-[#6]-[#7]-[#6](=O)-[#6@H](-[#6]-c2ccc(cc2)\[#7]=[#6](\[#7])-[#7])-[#7]-[#6](=O)-[#6]-[#7]-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@H](-[#6]-c2ccccc2)-[#7]-[#6](=O)-[#6@H](-[#6]-[#6]-[#6]-[#7]-[#6](-[#7])=[#7])-[#7]-[#6](=O)-[#6]-[#6]-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]-[#7]-[#6](-[#7])=[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-c2ccccc2)-[#6](=O)-[#7]-[#6@@H]2-[#6](=O)-[#7]-[#6@@H](-[#6@@H](-[#6])-[#8])-[#6](=O)-[#7]-[#6]-[#6](=O)-[#7]-[#6@@H](-[#6]-c3ccc(cc3)\[#7]=[#6](\[#7])-[#7])-[#6](=O)-[#7]-[#6]-[#6](=O)-[#7](-[#6])-[#6]-[#6](=O)-[#7](-[#6])-[#6@@H](-[#6]-[#6](-[#6])-[#6])-[#6](=O)-[#7]-[#6@@H](-[#6]-c3ccc(-[#8])cc3)-[#6](=O)-[#6](=O)-[#7]-3-[#6]-[#6]-[#6]-[#6@H]-3-[#6](=O)-[#7]-[#6@@H](-[#6]-[#16]-[#16]C2([#6])[#6])-[#6](-[#7])=O)C([#6])([#6])[#16]-[#16]-[#6]-[#6@H](-[#7]-[#6](=O)-[#6@@H]-2-[#6]-[#6]-[#6]-[#7]-2-[#6](=O)-[#6](=O)-[#6@H](-[#6]-c2ccc(-[#8])cc2)-[#7]-[#6]-1=O)-[#6](-[#7])=O)-[#6@@H](-[#6])-[#8] |r| Show InChI InChI=1S/C136H192N38O32S4/c1-71(2)55-97-123(199)159-87(57-79-37-45-83(177)46-38-79)109(187)129(205)173-53-23-31-95(173)121(197)163-93(113(137)189)69-207-209-135(7,8)111(127(203)165-107(73(5)175)125(201)149-63-101(181)157-89(61-77-33-41-81(42-34-77)153-133(143)144)115(191)151-65-103(183)169(11)67-105(185)171(97)13)167-119(195)91(59-75-25-17-15-18-26-75)161-117(193)85(29-21-51-147-131(139)140)155-99(179)49-50-100(180)156-86(30-22-52-148-132(141)142)118(194)162-92(60-76-27-19-16-20-28-76)120(196)168-112-128(204)166-108(74(6)176)126(202)150-64-102(182)158-90(62-78-35-43-82(44-36-78)154-134(145)146)116(192)152-66-104(184)170(12)68-106(186)172(14)98(56-72(3)4)124(200)160-88(58-80-39-47-84(178)48-40-80)110(188)130(206)174-54-24-32-96(174)122(198)164-94(114(138)190)70-208-210-136(112,9)10/h15-20,25-28,33-48,71-74,85-98,107-108,111-112,175-178H,21-24,29-32,49-70H2,1-14H3,(H2,137,189)(H2,138,190)(H,149,201)(H,150,202)(H,151,191)(H,152,192)(H,155,179)(H,156,180)(H,157,181)(H,158,182)(H,159,199)(H,160,200)(H,161,193)(H,162,194)(H,163,197)(H,164,198)(H,165,203)(H,166,204)(H,167,195)(H,168,196)(H4,139,140,147)(H4,141,142,148)(H4,143,144,153)(H4,145,146,154)/t73-,74-,85+,86+,87+,88+,89+,90+,91+,92+,93+,94+,95+,96+,97+,98+,107+,108+,111-,112-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 20 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314092
(CHEMBL1090280)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(=O)NCCCC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CCC(=O)NCCN(C)CC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC1=O)[C@@H](C)O)C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C155H216N42O37/c1-87(2)64-117-148(229)181-105(66-95-46-50-99(200)51-47-95)132(213)152(233)196-61-30-44-115(196)146(227)179-101(134(156)215)40-24-26-56-164-121(204)74-113(144(225)189-130(89(5)198)150(231)169-78-123(206)177-111(72-97-76-162-85-173-97)142(223)183-107(68-91-32-16-12-17-33-91)136(217)171-80-126(209)192(8)83-128(211)194(117)10)187-140(221)109(70-93-36-20-14-21-37-93)185-138(219)103(42-28-58-167-154(158)159)175-120(203)55-54-119(202)166-60-63-191(7)82-125(208)176-104(43-29-59-168-155(160)161)139(220)186-110(71-94-38-22-15-23-39-94)141(222)188-114-75-122(205)165-57-27-25-41-102(135(157)216)180-147(228)116-45-31-62-197(116)153(234)133(214)106(67-96-48-52-100(201)53-49-96)182-149(230)118(65-88(3)4)195(11)129(212)84-193(9)127(210)81-172-137(218)108(69-92-34-18-13-19-35-92)184-143(224)112(73-98-77-163-86-174-98)178-124(207)79-170-151(232)131(90(6)199)190-145(114)226/h12-23,32-39,46-53,76-77,85-90,101-118,130-131,198-201H,24-31,40-45,54-75,78-84H2,1-11H3,(H2,156,215)(H2,157,216)(H,162,173)(H,163,174)(H,164,204)(H,165,205)(H,166,202)(H,169,231)(H,170,232)(H,171,217)(H,172,218)(H,175,203)(H,176,208)(H,177,206)(H,178,207)(H,179,227)(H,180,228)(H,181,229)(H,182,230)(H,183,223)(H,184,224)(H,185,219)(H,186,220)(H,187,221)(H,188,222)(H,189,225)(H,190,226)(H4,158,159,167)(H4,160,161,168)/t89-,90-,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,130+,131+/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 50 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314078
((5S,8S,15S,18R,23R,26S,32S,35S,38S)-35-benzyl-23-[...)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN2CCC[C@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]3CCCN3C(=O)C(=O)[C@H](Cc3ccc(O)cc3)NC1=O)C(N)=O)[C@@H](C)O)C2=O |r| Show InChI InChI=1S/C75H103N19O17S2/c1-41(2)31-57-69(107)86-51(32-46-24-26-48(97)27-25-46)61(100)73(111)94-30-16-23-56(94)68(106)89-55(63(76)101)39-112-113-75(5,6)62(91-67(105)53(34-45-19-12-9-13-20-45)87-64(102)49(83-43(4)96)21-14-28-80-74(77)78)71(109)90-60(42(3)95)70(108)81-37-58(98)84-54(35-47-36-79-40-82-47)66(104)88-52(33-44-17-10-8-11-18-44)65(103)85-50-22-15-29-93(72(50)110)38-59(99)92(57)7/h8-13,17-20,24-27,36,40-42,49-57,60,62,95,97H,14-16,21-23,28-35,37-39H2,1-7H3,(H2,76,101)(H,79,82)(H,81,108)(H,83,96)(H,84,98)(H,85,103)(H,86,107)(H,87,102)(H,88,104)(H,89,106)(H,90,109)(H,91,105)(H4,77,78,80)/t42-,49+,50+,51+,52+,53+,54+,55+,56+,57+,60+,62-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 430 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314080
((3R,8R,11S,17S,20S,29S,32S,38aS)-17-((1H-imidazol-...)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C73H101N19O17S2/c1-40(2)29-55-68(106)84-49(30-45-23-25-47(95)26-24-45)60(99)71(109)92-28-16-22-54(92)67(105)87-53(62(74)100)38-110-111-73(5,6)61(89-66(104)51(32-44-19-13-10-14-20-44)86-64(102)48(82-42(4)94)21-15-27-78-72(75)76)70(108)88-59(41(3)93)69(107)79-35-56(96)83-52(33-46-34-77-39-81-46)65(103)85-50(31-43-17-11-9-12-18-43)63(101)80-36-57(97)90(7)37-58(98)91(55)8/h9-14,17-20,23-26,34,39-41,48-55,59,61,93,95H,15-16,21-22,27-33,35-38H2,1-8H3,(H2,74,100)(H,77,81)(H,79,107)(H,80,101)(H,82,94)(H,83,96)(H,84,106)(H,85,103)(H,86,102)(H,87,105)(H,88,108)(H,89,104)(H4,75,76,78)/t41-,48+,49+,50+,51+,52+,53+,54+,55+,59+,61-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 520 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314088
(CHEMBL1090276)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(=O)NCCCC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)CSCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC1=O)[C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C171H234N46O45S/c1-92(2)64-126-165(257)199-110(66-100-47-51-104(220)52-48-100)145(237)169(261)216-62-30-45-124(216)163(255)197-106(153(245)204-118(74-129(173)223)151(243)188-84-139(233)214-60-28-43-122(214)147(175)239)40-23-25-57-181-131(225)76-120(161(253)208-143(94(5)218)167(259)184-80-133(227)193-116(72-102-78-179-90-190-102)159(251)201-112(68-96-32-15-11-16-33-96)149(241)186-82-137(231)210(7)86-141(235)212(126)9)206-157(249)114(70-98-36-19-13-20-37-98)195-136(230)89-263-88-135(229)192-109(55-56-128(172)222)156(248)196-108(42-27-59-183-171(177)178)155(247)203-115(71-99-38-21-14-22-39-99)158(250)207-121-77-132(226)182-58-26-24-41-107(154(246)205-119(75-130(174)224)152(244)189-85-140(234)215-61-29-44-123(215)148(176)240)198-164(256)125-46-31-63-217(125)170(262)146(238)111(67-101-49-53-105(221)54-50-101)200-166(258)127(65-93(3)4)213(10)142(236)87-211(8)138(232)83-187-150(242)113(69-97-34-17-12-18-35-97)202-160(252)117(73-103-79-180-91-191-103)194-134(228)81-185-168(260)144(95(6)219)209-162(121)254/h11-22,32-39,47-54,78-79,90-95,106-127,143-144,218-221H,23-31,40-46,55-77,80-89H2,1-10H3,(H2,172,222)(H2,173,223)(H2,174,224)(H2,175,239)(H2,176,240)(H,179,190)(H,180,191)(H,181,225)(H,182,226)(H,184,259)(H,185,260)(H,186,241)(H,187,242)(H,188,243)(H,189,244)(H,192,229)(H,193,227)(H,194,228)(H,195,230)(H,196,248)(H,197,255)(H,198,256)(H,199,257)(H,200,258)(H,201,251)(H,202,252)(H,203,247)(H,204,245)(H,205,246)(H,206,249)(H,207,250)(H,208,253)(H,209,254)(H4,177,178,183)/t94-,95-,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,143+,144+/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 580 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314084
(CHEMBL1089952)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(=O)NCCCC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)CSCCC(=O)NCCCN(CCCNC(=O)CCSCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC1=O)[C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(N)=O)CC(=O)NCC(O)=O)[C@@H](C)O |r| Show InChI InChI=1S/C187H262N50O50S2/c1-104(2)74-138-181(282)218-122(76-112-49-53-116(240)54-50-112)161(262)185(286)236-70-30-47-136(236)179(280)216-118(169(270)223-130(84-141(189)243)167(268)207-94-154(256)234-68-28-45-134(234)163(191)264)42-23-25-61-199-145(247)86-132(177(278)227-159(106(5)238)183(284)203-90-147(249)212-128(82-114-88-195-102-209-114)175(276)220-124(78-108-34-15-11-16-35-108)165(266)205-92-152(254)229(7)98-156(258)231(138)9)225-173(274)126(80-110-38-19-13-20-39-110)214-151(253)101-289-73-60-144(246)198-65-33-67-233(97-149(251)202-96-158(260)261)66-32-64-197-143(245)59-72-288-100-150(252)211-121(57-58-140(188)242)172(273)215-120(44-27-63-201-187(193)194)171(272)222-127(81-111-40-21-14-22-41-111)174(275)226-133-87-146(248)200-62-26-24-43-119(170(271)224-131(85-142(190)244)168(269)208-95-155(257)235-69-29-46-135(235)164(192)265)217-180(281)137-48-31-71-237(137)186(287)162(263)123(77-113-51-55-117(241)56-52-113)219-182(283)139(75-105(3)4)232(10)157(259)99-230(8)153(255)93-206-166(267)125(79-109-36-17-12-18-37-109)221-176(277)129(83-115-89-196-103-210-115)213-148(250)91-204-184(285)160(107(6)239)228-178(133)279/h11-22,34-41,49-56,88-89,102-107,118-139,159-160,238-241H,23-33,42-48,57-87,90-101H2,1-10H3,(H2,188,242)(H2,189,243)(H2,190,244)(H2,191,264)(H2,192,265)(H,195,209)(H,196,210)(H,197,245)(H,198,246)(H,199,247)(H,200,248)(H,202,251)(H,203,284)(H,204,285)(H,205,266)(H,206,267)(H,207,268)(H,208,269)(H,211,252)(H,212,249)(H,213,250)(H,214,253)(H,215,273)(H,216,280)(H,217,281)(H,218,282)(H,219,283)(H,220,276)(H,221,277)(H,222,272)(H,223,270)(H,224,271)(H,225,274)(H,226,275)(H,227,278)(H,228,279)(H,260,261)(H4,193,194,201)/t106-,107-,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,159+,160+/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 600 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314087
(CHEMBL1090275)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(=O)NCCCC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)CSCCC(=O)NCCC(=O)NCCC(=O)NCCNCCCN(CCCNC(=O)CCNC(=O)CCNC(=O)CCNC(=O)CCSC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC1=O)[C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(N)=O)CC(=O)NCC(O)=O)[C@@H](C)O |r| Show InChI InChI=1S/C203H290N56O55S2/c1-115(2)86-149-196(308)239-133(88-123-49-53-127(262)54-50-123)176(288)200(312)258-82-30-47-147(258)194(306)237-129(184(296)244-141(96-152(205)265)182(294)229-106-169(282)256-80-28-45-145(256)178(207)290)42-23-25-67-215-161(274)98-143(192(304)249-174(117(5)260)198(310)225-102-163(276)233-139(94-125-100-212-113-231-125)190(302)241-135(90-119-34-15-11-16-35-119)180(292)227-104-167(280)251(7)110-171(284)253(149)9)246-188(300)137(92-121-38-19-13-20-39-121)235-166(279)112-315-84-64-159(272)220-74-61-156(269)219-73-63-158(271)222-77-76-211-66-32-78-255(109-165(278)224-108-173(286)287)79-33-70-214-154(267)59-71-217-155(268)60-72-218-157(270)62-75-221-160(273)65-85-316-203(314)248-132(57-58-151(204)264)187(299)236-131(44-27-69-223-202(209)210)186(298)243-138(93-122-40-21-14-22-41-122)189(301)247-144-99-162(275)216-68-26-24-43-130(185(297)245-142(97-153(206)266)183(295)230-107-170(283)257-81-29-46-146(257)179(208)291)238-195(307)148-48-31-83-259(148)201(313)177(289)134(89-124-51-55-128(263)56-52-124)240-197(309)150(87-116(3)4)254(10)172(285)111-252(8)168(281)105-228-181(293)136(91-120-36-17-12-18-37-120)242-191(303)140(95-126-101-213-114-232-126)234-164(277)103-226-199(311)175(118(6)261)250-193(144)305/h11-22,34-41,49-56,100-101,113-118,129-150,174-175,211,260-263H,23-33,42-48,57-99,102-112H2,1-10H3,(H2,204,264)(H2,205,265)(H2,206,266)(H2,207,290)(H2,208,291)(H,212,231)(H,213,232)(H,214,267)(H,215,274)(H,216,275)(H,217,268)(H,218,270)(H,219,269)(H,220,272)(H,221,273)(H,222,271)(H,224,278)(H,225,310)(H,226,311)(H,227,292)(H,228,293)(H,229,294)(H,230,295)(H,233,276)(H,234,277)(H,235,279)(H,236,299)(H,237,306)(H,238,307)(H,239,308)(H,240,309)(H,241,302)(H,242,303)(H,243,298)(H,244,296)(H,245,297)(H,246,300)(H,247,301)(H,248,314)(H,249,304)(H,250,305)(H,286,287)(H4,209,210,223)/t117-,118-,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,150+,174+,175+/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 710 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314081
((3R,8R,11S,17S,26S,29S,35aS)-8-((S)-2-((S)-2-aceta...)Show SMILES [#6]-[#6](-[#6])-[#6]-[#6@@H]-1-[#7](-[#6])-[#6](=O)-[#6]-[#7](-[#6])-[#6](=O)-[#6]-[#7]-[#6](=O)-[#6@H](-[#6]-c2ccc(cc2)\[#7]=[#6](\[#7])-[#7])-[#7]-[#6](=O)-[#6]-[#7]-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@H](-[#6]-c2ccccc2)-[#7]-[#6](=O)-[#6@H](-[#6]-[#6]-[#6]-[#7]-[#6](-[#7])=[#7])-[#7]-[#6](-[#6])=O)C([#6])([#6])[#16]-[#16]-[#6]-[#6@H](-[#7]-[#6](=O)-[#6@@H]-2-[#6]-[#6]-[#6]-[#7]-2-[#6](=O)-[#6](=O)-[#6@H](-[#6]-c2ccc(-[#8])cc2)-[#7]-[#6]-1=O)-[#6](-[#7])=O)-[#6@@H](-[#6])-[#8] |r| Show InChI InChI=1S/C68H97N19O16S2/c1-36(2)28-50-62(100)80-45(29-41-20-24-43(90)25-21-41)55(94)65(103)87-27-13-17-49(87)61(99)82-48(57(69)95)35-104-105-68(5,6)56(84-60(98)47(30-39-14-10-9-11-15-39)81-59(97)44(77-38(4)89)16-12-26-74-66(70)71)64(102)83-54(37(3)88)63(101)75-32-51(91)79-46(31-40-18-22-42(23-19-40)78-67(72)73)58(96)76-33-52(92)85(7)34-53(93)86(50)8/h9-11,14-15,18-25,36-37,44-50,54,56,88,90H,12-13,16-17,26-35H2,1-8H3,(H2,69,95)(H,75,101)(H,76,96)(H,77,89)(H,79,91)(H,80,100)(H,81,97)(H,82,99)(H,83,102)(H,84,98)(H4,70,71,74)(H4,72,73,78)/t37-,44+,45+,46+,47+,48+,49+,50+,54+,56-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314086
(CHEMBL1090274)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(=O)NCCCC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)CSCCC(=O)NCCC(=O)NCCC(=O)NCCCN(CCCNC(=O)CCNC(=O)CCSCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC1=O)[C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(N)=O)CC(=O)NCC(O)=O)[C@@H](C)O |r| Show InChI InChI=1S/C196H277N53O53S2/c1-110(2)80-144-190(297)230-128(82-118-49-53-122(252)54-50-118)170(277)194(301)248-76-30-47-142(248)188(295)228-124(178(285)235-136(90-147(198)255)176(283)219-100-163(271)246-74-28-45-140(246)172(200)279)42-23-25-64-208-154(262)92-138(186(293)239-168(112(5)250)192(299)215-96-156(264)224-134(88-120-94-204-108-221-120)184(291)232-130(84-114-34-15-11-16-35-114)174(281)217-98-161(269)241(7)104-165(273)243(144)9)237-182(289)132(86-116-38-19-13-20-39-116)226-160(268)107-304-79-63-153(261)212-71-61-151(259)210-69-59-149(257)206-67-32-72-245(103-158(266)214-102-167(275)276)73-33-68-207-150(258)60-70-211-152(260)62-78-303-106-159(267)223-127(57-58-146(197)254)181(288)227-126(44-27-66-213-196(202)203)180(287)234-133(87-117-40-21-14-22-41-117)183(290)238-139-93-155(263)209-65-26-24-43-125(179(286)236-137(91-148(199)256)177(284)220-101-164(272)247-75-29-46-141(247)173(201)280)229-189(296)143-48-31-77-249(143)195(302)171(278)129(83-119-51-55-123(253)56-52-119)231-191(298)145(81-111(3)4)244(10)166(274)105-242(8)162(270)99-218-175(282)131(85-115-36-17-12-18-37-115)233-185(292)135(89-121-95-205-109-222-121)225-157(265)97-216-193(300)169(113(6)251)240-187(139)294/h11-22,34-41,49-56,94-95,108-113,124-145,168-169,250-253H,23-33,42-48,57-93,96-107H2,1-10H3,(H2,197,254)(H2,198,255)(H2,199,256)(H2,200,279)(H2,201,280)(H,204,221)(H,205,222)(H,206,257)(H,207,258)(H,208,262)(H,209,263)(H,210,259)(H,211,260)(H,212,261)(H,214,266)(H,215,299)(H,216,300)(H,217,281)(H,218,282)(H,219,283)(H,220,284)(H,223,267)(H,224,264)(H,225,265)(H,226,268)(H,227,288)(H,228,295)(H,229,296)(H,230,297)(H,231,298)(H,232,291)(H,233,292)(H,234,287)(H,235,285)(H,236,286)(H,237,289)(H,238,290)(H,239,293)(H,240,294)(H,275,276)(H4,202,203,213)/t112-,113-,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,168+,169+/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 1.10E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314079
((5S,8S,15S,18R,23R,26S,32S,35S,38S)-35-benzyl-23-[...)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN2CCC[C@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)CNC(=O)[C@H](C)N(C)C(=O)[C@@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]3CCCN3C(=O)C(=O)[C@H](Cc3ccc(O)cc3)NC1=O)C(N)=O)C2=O |r| Show InChI InChI=1S/C75H103N19O16S2/c1-42(2)32-58-70(107)86-52(33-47-25-27-49(96)28-26-47)61(99)72(109)94-31-17-24-57(94)69(106)89-56(63(76)100)40-111-112-75(5,6)62(90-68(105)54(35-46-20-13-10-14-21-46)87-65(102)50(83-44(4)95)22-15-29-80-74(77)78)73(110)91(7)43(3)64(101)81-38-59(97)84-55(36-48-37-79-41-82-48)67(104)88-53(34-45-18-11-9-12-19-45)66(103)85-51-23-16-30-93(71(51)108)39-60(98)92(58)8/h9-14,18-21,25-28,37,41-43,50-58,62,96H,15-17,22-24,29-36,38-40H2,1-8H3,(H2,76,100)(H,79,82)(H,81,101)(H,83,95)(H,84,97)(H,85,103)(H,86,107)(H,87,102)(H,88,104)(H,89,106)(H,90,105)(H4,77,78,80)/t43-,50-,51-,52-,53-,54-,55-,56-,57-,58-,62+/m0/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 1.10E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314083
((3S,11S,14S,20S,23R,32S,35S,41aS)-20-((1H-imidazol...)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(=O)NCCCC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O)[C@@H](C)O |r| Show InChI InChI=1S/C75H104N20O18/c1-42(2)31-58-72(111)88-52(32-47-24-26-49(98)27-25-47)64(103)74(113)95-30-16-23-57(95)71(110)87-50(65(76)104)21-13-14-28-80-59(99)36-56(91-68(107)54(34-46-19-11-8-12-20-46)90-67(106)51(85-44(4)97)22-15-29-81-75(77)78)70(109)92-63(43(3)96)73(112)82-38-60(100)86-55(35-48-37-79-41-84-48)69(108)89-53(33-45-17-9-7-10-18-45)66(105)83-39-61(101)93(5)40-62(102)94(58)6/h7-12,17-20,24-27,37,41-43,50-58,63,96,98H,13-16,21-23,28-36,38-40H2,1-6H3,(H2,76,104)(H,79,84)(H,80,99)(H,82,112)(H,83,105)(H,85,97)(H,86,100)(H,87,110)(H,88,111)(H,89,108)(H,90,106)(H,91,107)(H,92,109)(H4,77,78,81)/t43-,50+,51+,52+,53?,54+,55+,56+,57+,58+,63+/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 1.90E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314085
(CHEMBL1090273)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(=O)NCCCC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)CSCCC(=O)NCCC(=O)NCCCN(C)CCCNC(=O)CCNC(=O)CCSCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC1=O)[C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C190H269N51O49S2/c1-107(2)79-141-184(285)222-125(81-115-50-54-119(244)55-51-115)164(265)188(289)240-75-31-48-139(240)182(283)220-121(172(273)227-133(89-144(192)247)170(271)211-99-158(261)238-73-29-46-137(238)166(194)267)43-24-26-64-202-150(253)91-135(180(281)231-162(109(5)242)186(287)207-95-152(255)216-131(87-117-93-198-105-213-117)178(279)224-127(83-111-35-16-12-17-36-111)168(269)209-97-156(259)234(8)101-160(263)236(141)10)229-176(277)129(85-113-39-20-14-21-40-113)218-155(258)104-292-78-63-149(252)205-70-61-147(250)201-68-34-72-233(7)71-33-67-200-146(249)60-69-204-148(251)62-77-291-103-154(257)215-124(58-59-143(191)246)175(276)219-123(45-28-66-206-190(196)197)174(275)226-130(86-114-41-22-15-23-42-114)177(278)230-136-92-151(254)203-65-27-25-44-122(173(274)228-134(90-145(193)248)171(272)212-100-159(262)239-74-30-47-138(239)167(195)268)221-183(284)140-49-32-76-241(140)189(290)165(266)126(82-116-52-56-120(245)57-53-116)223-185(286)142(80-108(3)4)237(11)161(264)102-235(9)157(260)98-210-169(270)128(84-112-37-18-13-19-38-112)225-179(280)132(88-118-94-199-106-214-118)217-153(256)96-208-187(288)163(110(6)243)232-181(136)282/h12-23,35-42,50-57,93-94,105-110,121-142,162-163,242-245H,24-34,43-49,58-92,95-104H2,1-11H3,(H2,191,246)(H2,192,247)(H2,193,248)(H2,194,267)(H2,195,268)(H,198,213)(H,199,214)(H,200,249)(H,201,250)(H,202,253)(H,203,254)(H,204,251)(H,205,252)(H,207,287)(H,208,288)(H,209,269)(H,210,270)(H,211,271)(H,212,272)(H,215,257)(H,216,255)(H,217,256)(H,218,258)(H,219,276)(H,220,283)(H,221,284)(H,222,285)(H,223,286)(H,224,279)(H,225,280)(H,226,275)(H,227,273)(H,228,274)(H,229,277)(H,230,278)(H,231,281)(H,232,282)(H4,196,197,206)/t109-,110-,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,162+,163+/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 2.40E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314089
(CHEMBL1090277)Show SMILES CC(C)C[C@@H]1NC(=O)CNC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CCC(=O)NCCN(C)CC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC1=O)[C@@H](C)O)C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C143H194N40O35S4/c1-77(2)52-95-128(205)169-93(54-85-36-40-89(186)41-37-85)120(197)140(217)182-49-22-34-107(182)136(213)175-103(122(144)199)71-219-221-73-105(134(211)179-118(79(5)184)138(215)159-68-115(194)167-101(60-87-62-150-75-161-87)132(209)171-97(56-81-24-12-8-13-25-81)124(201)157-64-111(190)155-66-113(192)165-95)177-130(207)99(58-83-28-16-10-17-29-83)173-126(203)91(32-20-46-153-142(146)147)163-110(189)45-44-109(188)152-48-51-181(7)70-117(196)164-92(33-21-47-154-143(148)149)127(204)174-100(59-84-30-18-11-19-31-84)131(208)178-106-74-222-220-72-104(123(145)200)176-137(214)108-35-23-50-183(108)141(218)121(198)94(55-86-38-42-90(187)43-39-86)170-129(206)96(53-78(3)4)166-114(193)67-156-112(191)65-158-125(202)98(57-82-26-14-9-15-27-82)172-133(210)102(61-88-63-151-76-162-88)168-116(195)69-160-139(216)119(80(6)185)180-135(106)212/h8-19,24-31,36-43,62-63,75-80,91-108,118-119,184-187H,20-23,32-35,44-61,64-74H2,1-7H3,(H2,144,199)(H2,145,200)(H,150,161)(H,151,162)(H,152,188)(H,155,190)(H,156,191)(H,157,201)(H,158,202)(H,159,215)(H,160,216)(H,163,189)(H,164,196)(H,165,192)(H,166,193)(H,167,194)(H,168,195)(H,169,205)(H,170,206)(H,171,209)(H,172,210)(H,173,203)(H,174,204)(H,175,213)(H,176,214)(H,177,207)(H,178,208)(H,179,211)(H,180,212)(H4,146,147,153)(H4,148,149,154)/t79-,80-,91+,92+,93+,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,118+,119+/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 3.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314082
(CHEMBL1089950)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(=O)NCCCC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(C)=O)[C@@H](C)O |r| Show InChI InChI=1S/C91H128N26O24/c1-49(2)36-68-88(139)108-60(37-54-26-28-56(120)29-27-54)77(128)90(141)117-35-17-25-67(117)87(138)107-57(81(132)111-64(41-70(93)122)80(131)102-46-74(126)116-34-16-24-66(116)78(94)129)22-13-14-32-98-71(123)42-65(112-84(135)62(39-53-20-11-8-12-21-53)110-82(133)58(23-15-33-99-91(95)96)106-83(134)59(104-51(4)119)30-31-69(92)121)86(137)113-76(50(3)118)89(140)100-44-72(124)105-63(40-55-43-97-48-103-55)85(136)109-61(38-52-18-9-7-10-19-52)79(130)101-45-73(125)114(5)47-75(127)115(68)6/h7-12,18-21,26-29,43,48-50,57-68,76,118,120H,13-17,22-25,30-42,44-47H2,1-6H3,(H2,92,121)(H2,93,122)(H2,94,129)(H,97,103)(H,98,123)(H,100,140)(H,101,130)(H,102,131)(H,104,119)(H,105,124)(H,106,134)(H,107,138)(H,108,139)(H,109,136)(H,110,133)(H,111,132)(H,112,135)(H,113,137)(H4,95,96,99)/t50-,57+,58+,59+,60+,61+,62+,63+,64+,65+,66+,67+,68+,76+/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 2.20E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314107
((3R,8R,11S,17S,20S,29S,32S,38aS)-17-((1H-imidazol-...)Show SMILES CC(C)C[C@@H]1NC(=O)CNC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O)[C@@H](C)O |r| Show InChI InChI=1S/C69H93N19O17S2/c1-37(2)25-47-62(99)82-46(26-42-19-21-44(91)22-20-42)58(95)68(105)88-24-12-18-53(88)66(103)85-51(59(70)96)34-106-107-35-52(86-63(100)49(28-41-15-9-6-10-16-41)84-61(98)45(79-39(4)90)17-11-23-74-69(71)72)65(102)87-57(38(3)89)67(104)77-33-56(94)81-50(29-43-30-73-36-78-43)64(101)83-48(27-40-13-7-5-8-14-40)60(97)76-31-54(92)75-32-55(93)80-47/h5-10,13-16,19-22,30,36-38,45-53,57,89,91H,11-12,17-18,23-29,31-35H2,1-4H3,(H2,70,96)(H,73,78)(H,75,92)(H,76,97)(H,77,104)(H,79,90)(H,80,93)(H,81,94)(H,82,99)(H,83,101)(H,84,98)(H,85,103)(H,86,100)(H,87,102)(H4,71,72,74)/t38-,45+,46+,47+,48+,49+,50+,51+,52+,53+,57+/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 3.70E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314106
((S)-N1-((S)-1-((S)-1-((3R,8R,11S,17S,20S,29S,32S,3...)Show SMILES CC(C)C[C@@H]1NC(=O)CNC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(C)=O)[C@@H](C)O |r| Show InChI InChI=1S/C85H117N25O23S2/c1-44(2)30-55-77(126)102-54(31-49-21-23-51(113)24-22-49)71(120)84(133)110-29-13-20-63(110)82(131)107-60(80(129)105-59(35-65(87)115)74(123)96-40-69(119)109-28-12-19-62(109)72(88)121)41-134-135-42-61(106-78(127)57(33-48-16-9-6-10-17-48)104-75(124)52(18-11-27-92-85(89)90)101-76(125)53(98-46(4)112)25-26-64(86)114)81(130)108-70(45(3)111)83(132)95-39-68(118)100-58(34-50-36-91-43-97-50)79(128)103-56(32-47-14-7-5-8-15-47)73(122)94-37-66(116)93-38-67(117)99-55/h5-10,14-17,21-24,36,43-45,52-63,70,111,113H,11-13,18-20,25-35,37-42H2,1-4H3,(H2,86,114)(H2,87,115)(H2,88,121)(H,91,97)(H,93,116)(H,94,122)(H,95,132)(H,96,123)(H,98,112)(H,99,117)(H,100,118)(H,101,125)(H,102,126)(H,103,128)(H,104,124)(H,105,129)(H,106,127)(H,107,131)(H,108,130)(H4,89,90,92)/t45-,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,63+,70+/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 4.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314078
((5S,8S,15S,18R,23R,26S,32S,35S,38S)-35-benzyl-23-[...)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN2CCC[C@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]3CCCN3C(=O)C(=O)[C@H](Cc3ccc(O)cc3)NC1=O)C(N)=O)[C@@H](C)O)C2=O |r| Show InChI InChI=1S/C75H103N19O17S2/c1-41(2)31-57-69(107)86-51(32-46-24-26-48(97)27-25-46)61(100)73(111)94-30-16-23-56(94)68(106)89-55(63(76)101)39-112-113-75(5,6)62(91-67(105)53(34-45-19-12-9-13-20-45)87-64(102)49(83-43(4)96)21-14-28-80-74(77)78)71(109)90-60(42(3)95)70(108)81-37-58(98)84-54(35-47-36-79-40-82-47)66(104)88-52(33-44-17-10-8-11-18-44)65(103)85-50-22-15-29-93(72(50)110)38-59(99)92(57)7/h8-13,17-20,24-27,36,40-42,49-57,60,62,95,97H,14-16,21-23,28-35,37-39H2,1-7H3,(H2,76,101)(H,79,82)(H,81,108)(H,83,96)(H,84,98)(H,85,103)(H,86,107)(H,87,102)(H,88,104)(H,89,106)(H,90,109)(H,91,105)(H4,77,78,80)/t42-,49+,50+,51+,52+,53+,54+,55+,56+,57+,60+,62-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | 43 | n/a | n/a | n/a | 6.0 | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Binding affinity to soluble human FcRn at pH 6 by surface plasmon resonance assay |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314083
((3S,11S,14S,20S,23R,32S,35S,41aS)-20-((1H-imidazol...)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(=O)NCCCC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O)[C@@H](C)O |r| Show InChI InChI=1S/C75H104N20O18/c1-42(2)31-58-72(111)88-52(32-47-24-26-49(98)27-25-47)64(103)74(113)95-30-16-23-57(95)71(110)87-50(65(76)104)21-13-14-28-80-59(99)36-56(91-68(107)54(34-46-19-11-8-12-20-46)90-67(106)51(85-44(4)97)22-15-29-81-75(77)78)70(109)92-63(43(3)96)73(112)82-38-60(100)86-55(35-48-37-79-41-84-48)69(108)89-53(33-45-17-9-7-10-18-45)66(105)83-39-61(101)93(5)40-62(102)94(58)6/h7-12,17-20,24-27,37,41-43,50-58,63,96,98H,13-16,21-23,28-36,38-40H2,1-6H3,(H2,76,104)(H,79,84)(H,80,99)(H,82,112)(H,83,105)(H,85,97)(H,86,100)(H,87,110)(H,88,111)(H,89,108)(H,90,106)(H,91,107)(H,92,109)(H4,77,78,81)/t43-,50+,51+,52+,53?,54+,55+,56+,57+,58+,63+/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | 140 | n/a | n/a | n/a | 6.0 | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Binding affinity to soluble human FcRn at pH 6 by surface plasmon resonance assay |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314107
((3R,8R,11S,17S,20S,29S,32S,38aS)-17-((1H-imidazol-...)Show SMILES CC(C)C[C@@H]1NC(=O)CNC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O)[C@@H](C)O |r| Show InChI InChI=1S/C69H93N19O17S2/c1-37(2)25-47-62(99)82-46(26-42-19-21-44(91)22-20-42)58(95)68(105)88-24-12-18-53(88)66(103)85-51(59(70)96)34-106-107-35-52(86-63(100)49(28-41-15-9-6-10-16-41)84-61(98)45(79-39(4)90)17-11-23-74-69(71)72)65(102)87-57(38(3)89)67(104)77-33-56(94)81-50(29-43-30-73-36-78-43)64(101)83-48(27-40-13-7-5-8-14-40)60(97)76-31-54(92)75-32-55(93)80-47/h5-10,13-16,19-22,30,36-38,45-53,57,89,91H,11-12,17-18,23-29,31-35H2,1-4H3,(H2,70,96)(H,73,78)(H,75,92)(H,76,97)(H,77,104)(H,79,90)(H,80,93)(H,81,94)(H,82,99)(H,83,101)(H,84,98)(H,85,103)(H,86,100)(H,87,102)(H4,71,72,74)/t38-,45+,46+,47+,48+,49+,50+,51+,52+,53+,57+/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | 5.90E+3 | n/a | n/a | n/a | 6.0 | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Binding affinity to soluble human FcRn at pH 6 by surface plasmon resonance assay |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314079
((5S,8S,15S,18R,23R,26S,32S,35S,38S)-35-benzyl-23-[...)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN2CCC[C@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)CNC(=O)[C@H](C)N(C)C(=O)[C@@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]3CCCN3C(=O)C(=O)[C@H](Cc3ccc(O)cc3)NC1=O)C(N)=O)C2=O |r| Show InChI InChI=1S/C75H103N19O16S2/c1-42(2)32-58-70(107)86-52(33-47-25-27-49(96)28-26-47)61(99)72(109)94-31-17-24-57(94)69(106)89-56(63(76)100)40-111-112-75(5,6)62(90-68(105)54(35-46-20-13-10-14-21-46)87-65(102)50(83-44(4)95)22-15-29-80-74(77)78)73(110)91(7)43(3)64(101)81-38-59(97)84-55(36-48-37-79-41-82-48)67(104)88-53(34-45-18-11-9-12-19-45)66(103)85-51-23-16-30-93(71(51)108)39-60(98)92(58)8/h9-14,18-21,25-28,37,41-43,50-58,62,96H,15-17,22-24,29-36,38-40H2,1-8H3,(H2,76,100)(H,79,82)(H,81,101)(H,83,95)(H,84,97)(H,85,103)(H,86,107)(H,87,102)(H,88,104)(H,89,106)(H,90,105)(H4,77,78,80)/t43-,50-,51-,52-,53-,54-,55-,56-,57-,58-,62+/m0/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | 950 | n/a | n/a | n/a | 7.4 | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Binding affinity to soluble human FcRn at pH 7.4 by surface plasmon resonance assay |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314082
(CHEMBL1089950)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(=O)NCCCC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(C)=O)[C@@H](C)O |r| Show InChI InChI=1S/C91H128N26O24/c1-49(2)36-68-88(139)108-60(37-54-26-28-56(120)29-27-54)77(128)90(141)117-35-17-25-67(117)87(138)107-57(81(132)111-64(41-70(93)122)80(131)102-46-74(126)116-34-16-24-66(116)78(94)129)22-13-14-32-98-71(123)42-65(112-84(135)62(39-53-20-11-8-12-21-53)110-82(133)58(23-15-33-99-91(95)96)106-83(134)59(104-51(4)119)30-31-69(92)121)86(137)113-76(50(3)118)89(140)100-44-72(124)105-63(40-55-43-97-48-103-55)85(136)109-61(38-52-18-9-7-10-19-52)79(130)101-45-73(125)114(5)47-75(127)115(68)6/h7-12,18-21,26-29,43,48-50,57-68,76,118,120H,13-17,22-25,30-42,44-47H2,1-6H3,(H2,92,121)(H2,93,122)(H2,94,129)(H,97,103)(H,98,123)(H,100,140)(H,101,130)(H,102,131)(H,104,119)(H,105,124)(H,106,134)(H,107,138)(H,108,139)(H,109,136)(H,110,133)(H,111,132)(H,112,135)(H,113,137)(H4,95,96,99)/t50-,57+,58+,59+,60+,61+,62+,63+,64+,65+,66+,67+,68+,76+/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | 2.60E+3 | n/a | n/a | n/a | 6.0 | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Binding affinity to soluble human FcRn at pH 6 by surface plasmon resonance assay |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314081
((3R,8R,11S,17S,26S,29S,35aS)-8-((S)-2-((S)-2-aceta...)Show SMILES [#6]-[#6](-[#6])-[#6]-[#6@@H]-1-[#7](-[#6])-[#6](=O)-[#6]-[#7](-[#6])-[#6](=O)-[#6]-[#7]-[#6](=O)-[#6@H](-[#6]-c2ccc(cc2)\[#7]=[#6](\[#7])-[#7])-[#7]-[#6](=O)-[#6]-[#7]-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@H](-[#6]-c2ccccc2)-[#7]-[#6](=O)-[#6@H](-[#6]-[#6]-[#6]-[#7]-[#6](-[#7])=[#7])-[#7]-[#6](-[#6])=O)C([#6])([#6])[#16]-[#16]-[#6]-[#6@H](-[#7]-[#6](=O)-[#6@@H]-2-[#6]-[#6]-[#6]-[#7]-2-[#6](=O)-[#6](=O)-[#6@H](-[#6]-c2ccc(-[#8])cc2)-[#7]-[#6]-1=O)-[#6](-[#7])=O)-[#6@@H](-[#6])-[#8] |r| Show InChI InChI=1S/C68H97N19O16S2/c1-36(2)28-50-62(100)80-45(29-41-20-24-43(90)25-21-41)55(94)65(103)87-27-13-17-49(87)61(99)82-48(57(69)95)35-104-105-68(5,6)56(84-60(98)47(30-39-14-10-9-11-15-39)81-59(97)44(77-38(4)89)16-12-26-74-66(70)71)64(102)83-54(37(3)88)63(101)75-32-51(91)79-46(31-40-18-22-42(23-19-40)78-67(72)73)58(96)76-33-52(92)85(7)34-53(93)86(50)8/h9-11,14-15,18-25,36-37,44-50,54,56,88,90H,12-13,16-17,26-35H2,1-8H3,(H2,69,95)(H,75,101)(H,76,96)(H,77,89)(H,79,91)(H,80,100)(H,81,97)(H,82,99)(H,83,102)(H,84,98)(H4,70,71,74)(H4,72,73,78)/t37-,44+,45+,46+,47+,48+,49+,50+,54+,56-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | 62 | n/a | n/a | n/a | 6.0 | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Binding affinity to soluble human FcRn at pH 6 by surface plasmon resonance assay |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314080
((3R,8R,11S,17S,20S,29S,32S,38aS)-17-((1H-imidazol-...)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C73H101N19O17S2/c1-40(2)29-55-68(106)84-49(30-45-23-25-47(95)26-24-45)60(99)71(109)92-28-16-22-54(92)67(105)87-53(62(74)100)38-110-111-73(5,6)61(89-66(104)51(32-44-19-13-10-14-20-44)86-64(102)48(82-42(4)94)21-15-27-78-72(75)76)70(108)88-59(41(3)93)69(107)79-35-56(96)83-52(33-46-34-77-39-81-46)65(103)85-50(31-43-17-11-9-12-18-43)63(101)80-36-57(97)90(7)37-58(98)91(55)8/h9-14,17-20,23-26,34,39-41,48-55,59,61,93,95H,15-16,21-22,27-33,35-38H2,1-8H3,(H2,74,100)(H,77,81)(H,79,107)(H,80,101)(H,82,94)(H,83,96)(H,84,106)(H,85,103)(H,86,102)(H,87,105)(H,88,108)(H,89,104)(H4,75,76,78)/t41-,48+,49+,50+,51+,52+,53+,54+,55+,59+,61-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | 170 | n/a | n/a | n/a | 7.4 | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Binding affinity to soluble human FcRn at pH 7.4 by surface plasmon resonance assay |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314083
((3S,11S,14S,20S,23R,32S,35S,41aS)-20-((1H-imidazol...)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(=O)NCCCC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O)[C@@H](C)O |r| Show InChI InChI=1S/C75H104N20O18/c1-42(2)31-58-72(111)88-52(32-47-24-26-49(98)27-25-47)64(103)74(113)95-30-16-23-57(95)71(110)87-50(65(76)104)21-13-14-28-80-59(99)36-56(91-68(107)54(34-46-19-11-8-12-20-46)90-67(106)51(85-44(4)97)22-15-29-81-75(77)78)70(109)92-63(43(3)96)73(112)82-38-60(100)86-55(35-48-37-79-41-84-48)69(108)89-53(33-45-17-9-7-10-18-45)66(105)83-39-61(101)93(5)40-62(102)94(58)6/h7-12,17-20,24-27,37,41-43,50-58,63,96,98H,13-16,21-23,28-36,38-40H2,1-6H3,(H2,76,104)(H,79,84)(H,80,99)(H,82,112)(H,83,105)(H,85,97)(H,86,100)(H,87,110)(H,88,111)(H,89,108)(H,90,106)(H,91,107)(H,92,109)(H4,77,78,81)/t43-,50+,51+,52+,53?,54+,55+,56+,57+,58+,63+/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | 930 | n/a | n/a | n/a | 7.4 | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Binding affinity to soluble human FcRn at pH 7.4 by surface plasmon resonance assay |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314106
((S)-N1-((S)-1-((S)-1-((3R,8R,11S,17S,20S,29S,32S,3...)Show SMILES CC(C)C[C@@H]1NC(=O)CNC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(C)=O)[C@@H](C)O |r| Show InChI InChI=1S/C85H117N25O23S2/c1-44(2)30-55-77(126)102-54(31-49-21-23-51(113)24-22-49)71(120)84(133)110-29-13-20-63(110)82(131)107-60(80(129)105-59(35-65(87)115)74(123)96-40-69(119)109-28-12-19-62(109)72(88)121)41-134-135-42-61(106-78(127)57(33-48-16-9-6-10-17-48)104-75(124)52(18-11-27-92-85(89)90)101-76(125)53(98-46(4)112)25-26-64(86)114)81(130)108-70(45(3)111)83(132)95-39-68(118)100-58(34-50-36-91-43-97-50)79(128)103-56(32-47-14-7-5-8-15-47)73(122)94-37-66(116)93-38-67(117)99-55/h5-10,14-17,21-24,36,43-45,52-63,70,111,113H,11-13,18-20,25-35,37-42H2,1-4H3,(H2,86,114)(H2,87,115)(H2,88,121)(H,91,97)(H,93,116)(H,94,122)(H,95,132)(H,96,123)(H,98,112)(H,99,117)(H,100,118)(H,101,125)(H,102,126)(H,103,128)(H,104,124)(H,105,129)(H,106,127)(H,107,131)(H,108,130)(H4,89,90,92)/t45-,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,63+,70+/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | 5.30E+3 | n/a | n/a | n/a | 6.0 | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Binding affinity to soluble human FcRn at pH 6 by surface plasmon resonance assay |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314081
((3R,8R,11S,17S,26S,29S,35aS)-8-((S)-2-((S)-2-aceta...)Show SMILES [#6]-[#6](-[#6])-[#6]-[#6@@H]-1-[#7](-[#6])-[#6](=O)-[#6]-[#7](-[#6])-[#6](=O)-[#6]-[#7]-[#6](=O)-[#6@H](-[#6]-c2ccc(cc2)\[#7]=[#6](\[#7])-[#7])-[#7]-[#6](=O)-[#6]-[#7]-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@H](-[#6]-c2ccccc2)-[#7]-[#6](=O)-[#6@H](-[#6]-[#6]-[#6]-[#7]-[#6](-[#7])=[#7])-[#7]-[#6](-[#6])=O)C([#6])([#6])[#16]-[#16]-[#6]-[#6@H](-[#7]-[#6](=O)-[#6@@H]-2-[#6]-[#6]-[#6]-[#7]-2-[#6](=O)-[#6](=O)-[#6@H](-[#6]-c2ccc(-[#8])cc2)-[#7]-[#6]-1=O)-[#6](-[#7])=O)-[#6@@H](-[#6])-[#8] |r| Show InChI InChI=1S/C68H97N19O16S2/c1-36(2)28-50-62(100)80-45(29-41-20-24-43(90)25-21-41)55(94)65(103)87-27-13-17-49(87)61(99)82-48(57(69)95)35-104-105-68(5,6)56(84-60(98)47(30-39-14-10-9-11-15-39)81-59(97)44(77-38(4)89)16-12-26-74-66(70)71)64(102)83-54(37(3)88)63(101)75-32-51(91)79-46(31-40-18-22-42(23-19-40)78-67(72)73)58(96)76-33-52(92)85(7)34-53(93)86(50)8/h9-11,14-15,18-25,36-37,44-50,54,56,88,90H,12-13,16-17,26-35H2,1-8H3,(H2,69,95)(H,75,101)(H,76,96)(H,77,89)(H,79,91)(H,80,100)(H,81,97)(H,82,99)(H,83,102)(H,84,98)(H4,70,71,74)(H4,72,73,78)/t37-,44+,45+,46+,47+,48+,49+,50+,54+,56-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | 74 | n/a | n/a | n/a | 7.4 | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Binding affinity to soluble human FcRn at pH 7.4 by surface plasmon resonance assay |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314079
((5S,8S,15S,18R,23R,26S,32S,35S,38S)-35-benzyl-23-[...)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN2CCC[C@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)CNC(=O)[C@H](C)N(C)C(=O)[C@@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]3CCCN3C(=O)C(=O)[C@H](Cc3ccc(O)cc3)NC1=O)C(N)=O)C2=O |r| Show InChI InChI=1S/C75H103N19O16S2/c1-42(2)32-58-70(107)86-52(33-47-25-27-49(96)28-26-47)61(99)72(109)94-31-17-24-57(94)69(106)89-56(63(76)100)40-111-112-75(5,6)62(90-68(105)54(35-46-20-13-10-14-21-46)87-65(102)50(83-44(4)95)22-15-29-80-74(77)78)73(110)91(7)43(3)64(101)81-38-59(97)84-55(36-48-37-79-41-82-48)67(104)88-53(34-45-18-11-9-12-19-45)66(103)85-51-23-16-30-93(71(51)108)39-60(98)92(58)8/h9-14,18-21,25-28,37,41-43,50-58,62,96H,15-17,22-24,29-36,38-40H2,1-8H3,(H2,76,100)(H,79,82)(H,81,101)(H,83,95)(H,84,97)(H,85,103)(H,86,107)(H,87,102)(H,88,104)(H,89,106)(H,90,105)(H4,77,78,80)/t43-,50-,51-,52-,53-,54-,55-,56-,57-,58-,62+/m0/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | 150 | n/a | n/a | n/a | 6.0 | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Binding affinity to soluble human FcRn at pH 6 by surface plasmon resonance assay |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314082
(CHEMBL1089950)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(=O)NCCCC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(C)=O)[C@@H](C)O |r| Show InChI InChI=1S/C91H128N26O24/c1-49(2)36-68-88(139)108-60(37-54-26-28-56(120)29-27-54)77(128)90(141)117-35-17-25-67(117)87(138)107-57(81(132)111-64(41-70(93)122)80(131)102-46-74(126)116-34-16-24-66(116)78(94)129)22-13-14-32-98-71(123)42-65(112-84(135)62(39-53-20-11-8-12-21-53)110-82(133)58(23-15-33-99-91(95)96)106-83(134)59(104-51(4)119)30-31-69(92)121)86(137)113-76(50(3)118)89(140)100-44-72(124)105-63(40-55-43-97-48-103-55)85(136)109-61(38-52-18-9-7-10-19-52)79(130)101-45-73(125)114(5)47-75(127)115(68)6/h7-12,18-21,26-29,43,48-50,57-68,76,118,120H,13-17,22-25,30-42,44-47H2,1-6H3,(H2,92,121)(H2,93,122)(H2,94,129)(H,97,103)(H,98,123)(H,100,140)(H,101,130)(H,102,131)(H,104,119)(H,105,124)(H,106,134)(H,107,138)(H,108,139)(H,109,136)(H,110,133)(H,111,132)(H,112,135)(H,113,137)(H4,95,96,99)/t50-,57+,58+,59+,60+,61+,62+,63+,64+,65+,66+,67+,68+,76+/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | 1.80E+4 | n/a | n/a | n/a | 7.4 | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Binding affinity to soluble human FcRn at pH 7.4 by surface plasmon resonance assay |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314080
((3R,8R,11S,17S,20S,29S,32S,38aS)-17-((1H-imidazol-...)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C73H101N19O17S2/c1-40(2)29-55-68(106)84-49(30-45-23-25-47(95)26-24-45)60(99)71(109)92-28-16-22-54(92)67(105)87-53(62(74)100)38-110-111-73(5,6)61(89-66(104)51(32-44-19-13-10-14-20-44)86-64(102)48(82-42(4)94)21-15-27-78-72(75)76)70(108)88-59(41(3)93)69(107)79-35-56(96)83-52(33-46-34-77-39-81-46)65(103)85-50(31-43-17-11-9-12-18-43)63(101)80-36-57(97)90(7)37-58(98)91(55)8/h9-14,17-20,23-26,34,39-41,48-55,59,61,93,95H,15-16,21-22,27-33,35-38H2,1-8H3,(H2,74,100)(H,77,81)(H,79,107)(H,80,101)(H,82,94)(H,83,96)(H,84,106)(H,85,103)(H,86,102)(H,87,105)(H,88,108)(H,89,104)(H4,75,76,78)/t41-,48+,49+,50+,51+,52+,53+,54+,55+,59+,61-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | 31 | n/a | n/a | n/a | 6.0 | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Binding affinity to soluble human FcRn at pH 6 by surface plasmon resonance assay |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314106
((S)-N1-((S)-1-((S)-1-((3R,8R,11S,17S,20S,29S,32S,3...)Show SMILES CC(C)C[C@@H]1NC(=O)CNC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(C)=O)[C@@H](C)O |r| Show InChI InChI=1S/C85H117N25O23S2/c1-44(2)30-55-77(126)102-54(31-49-21-23-51(113)24-22-49)71(120)84(133)110-29-13-20-63(110)82(131)107-60(80(129)105-59(35-65(87)115)74(123)96-40-69(119)109-28-12-19-62(109)72(88)121)41-134-135-42-61(106-78(127)57(33-48-16-9-6-10-17-48)104-75(124)52(18-11-27-92-85(89)90)101-76(125)53(98-46(4)112)25-26-64(86)114)81(130)108-70(45(3)111)83(132)95-39-68(118)100-58(34-50-36-91-43-97-50)79(128)103-56(32-47-14-7-5-8-15-47)73(122)94-37-66(116)93-38-67(117)99-55/h5-10,14-17,21-24,36,43-45,52-63,70,111,113H,11-13,18-20,25-35,37-42H2,1-4H3,(H2,86,114)(H2,87,115)(H2,88,121)(H,91,97)(H,93,116)(H,94,122)(H,95,132)(H,96,123)(H,98,112)(H,99,117)(H,100,118)(H,101,125)(H,102,126)(H,103,128)(H,104,124)(H,105,129)(H,106,127)(H,107,131)(H,108,130)(H4,89,90,92)/t45-,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,63+,70+/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | 3.70E+4 | n/a | n/a | n/a | 7.4 | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Binding affinity to soluble human FcRn at pH 7.4 by surface plasmon resonance assay |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314078
((5S,8S,15S,18R,23R,26S,32S,35S,38S)-35-benzyl-23-[...)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN2CCC[C@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]3CCCN3C(=O)C(=O)[C@H](Cc3ccc(O)cc3)NC1=O)C(N)=O)[C@@H](C)O)C2=O |r| Show InChI InChI=1S/C75H103N19O17S2/c1-41(2)31-57-69(107)86-51(32-46-24-26-48(97)27-25-46)61(100)73(111)94-30-16-23-56(94)68(106)89-55(63(76)101)39-112-113-75(5,6)62(91-67(105)53(34-45-19-12-9-13-20-45)87-64(102)49(83-43(4)96)21-14-28-80-74(77)78)71(109)90-60(42(3)95)70(108)81-37-58(98)84-54(35-47-36-79-40-82-47)66(104)88-52(33-44-17-10-8-11-18-44)65(103)85-50-22-15-29-93(72(50)110)38-59(99)92(57)7/h8-13,17-20,24-27,36,40-42,49-57,60,62,95,97H,14-16,21-23,28-35,37-39H2,1-7H3,(H2,76,101)(H,79,82)(H,81,108)(H,83,96)(H,84,98)(H,85,103)(H,86,107)(H,87,102)(H,88,104)(H,89,106)(H,90,109)(H,91,105)(H4,77,78,80)/t42-,49+,50+,51+,52+,53+,54+,55+,56+,57+,60+,62-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | 260 | n/a | n/a | n/a | 7.4 | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Binding affinity to soluble human FcRn at pH 7.4 by surface plasmon resonance assay |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
Search and Browse
